• Breast Cancer and HER2-Low: A Distinct Biology or an Artifact of Testing?

  • 2024/08/20
  • 再生時間： 25 分
  • ポッドキャスト

Breast Cancer and HER2-Low: A Distinct Biology or an Artifact of Testing?

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • Drs Kathy D. Miller and Sunil S. Badve discuss the importance of identifying HER2-low patients, those with ultra-low staining, and the benefit of targeted ADCs.

    Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001160. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview

    Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update https://pubmed.ncbi.nlm.nih.gov/37284804/

    T-DXd Improves Progression-Free Survival in Patients With Breast Cancer Previously Treated With Endocrine Therapy https://ascopost.com/news/june-2024/t-dxd-improves-progression-free-survival-in-patients-with-breast-cancer-previously-treated-with-endocrine-therapy/

    Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients With Residual HER2-Positive Invasive Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34636255/
    続きを読む 一部表示

あらすじ・解説

Drs Kathy D. Miller and Sunil S. Badve discuss the importance of identifying HER2-low patients, those with ultra-low staining, and the benefit of targeted ADCs.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001160. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update https://pubmed.ncbi.nlm.nih.gov/37284804/

T-DXd Improves Progression-Free Survival in Patients With Breast Cancer Previously Treated With Endocrine Therapy https://ascopost.com/news/june-2024/t-dxd-improves-progression-free-survival-in-patients-with-breast-cancer-previously-treated-with-endocrine-therapy/

Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients With Residual HER2-Positive Invasive Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34636255/
身体的病い・疾患 衛生・健康的な生活 科学
続きを読む 一部表示

Breast Cancer and HER2-Low: A Distinct Biology or an Artifact of Testing?に寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。